Spectral MD https://www.spectralmd.com has received funding from the Biomedical Advanced Research and Development Authority (BARDA) within the HHS Office of the Assistant Secretary for Preparedness and Response https://www.phe.gov to continue to develop Spectral MD’s DeepView®. The biomedical imaging device is used to more effectively manage advanced burn and wound care. Deep view is a compact and portable diagnostic medical device that embodies Artificial Intelligence (AI).
BARDA will provide $27 million over 22 months with options for additional funding up to $92 million to conduct an expanded proof of concept clinical trial that would target advance burn care assessment and then expand to include the pediatric population.
“DeepView, is an advanced technology capable of analyzing tissue characteristics to identify the boundaries of dead, damaged, and healthy tissue without even touching the patient”, explained J. Michael DiMaio, MD, CEO of Spectral MD. “DeepView is portable and intended to be positioned over any area of the body to provide rapid real-time results to allow more accurate determination than is possible with human assessment.”
The portable non-invasive device relies on deep learning algorithms and AI to assist clinicians in diagnosing and improving patient treatment decisions and outcomes. AI can identify precise areas to establish where dead tissue ends and live tissue begins which helps surgeons reduce the size and amount of skin grafting needed to improve surgical outcomes.
In addition to everyday applications, DeepView is going to be able to improve the healthcare system’s response to burn patients in a national emergency. For example, in the case of a radiological or nuclear emergency, surgeons could possibly save thousands of patients in need of immediate life-saving skin grafts.
Go to https://www.phe.gov/about/barda/Pages/default.aspx for more information on BARDA.